Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2126)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of JW (Cayman) Therapeutics Co. Ltd (the "**Company**") dated September 16, 2025 in relation to grant of Options pursuant to the Post-IPO Incentivization Scheme (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the "**Circular**") containing, among other things, details of the grant of Options to Mr. Liu under the Post-IPO Incentivization Scheme and a notice of the EGM will be despatched to the Shareholders in accordance with the Listing Rules. As additional time is required for the Company to prepare and finalize certain information to be included in the Circular, the Company now expects to despatch the Circular on or before December 31, 2025.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Min Liu
Chairman

Shanghai, PRC, September 30, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Min Liu as Chairman and executive Director, Dr. Yiping James Li, Ms. Xing Gao, Dr. Sungwon Song and Dr. Cheng Liu as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.

* *For identification purpose only*